Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis

Area of Science:

• Neuroscience
• Neurology
• Biomarker Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with overlapping pathology with frontotemporal dementia.
• Current therapeutic trials in animal models have limited predictive value for human treatment response.
• The revised ALS Functional Rating Scale, a measure of disability, is the standard for tracking disease progression.

Purpose of the Study:

• To explore the potential of neuroimaging techniques for mapping ALS pathology.
• To investigate objective measures for detecting early disease progression and propagation in vivo.
• To assess the suitability of neuroimaging biomarkers as outcome measures for therapeutic interventions.

Main Methods:

• Utilizing advances in neuroimaging to map functional, structural, and molecular aspects of ALS pathology.
• Identifying abnormalities detectable before the onset of clinical symptoms.
• Analyzing data from select patient cohorts in specialized referral centers.

Main Results:

• Neuroimaging enables objective mapping of ALS pathology, potentially detecting abnormalities before clinical manifestation.
• Abnormalities identified through neuroimaging may indicate early disease propagation in vivo.
• Promising neuroimaging biomarker candidates for diagnosis, prognosis, and disease progression have emerged.

Conclusions:

• Neuroimaging offers sensitive, objective measures for detecting ALS pathology and progression.
• Early detection via neuroimaging may enable timely neuroprotective interventions, particularly in familial ALS.
• Multicenter research is crucial to validate these neuroimaging biomarkers as reliable outcome measures for clinical trials.